Near real-time adverse drug reaction surveillance within population-based health networks: Methodology considerations for data accrual

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 5, 2013, Pages 488-495

  Avery, Taliser R ^a,b   Kulldorff, Martin ^a,b   Vilk, Yury ^a   Li, Lingling ^a   Craig Cheetham, T ^b,c   Dublin, Sascha ^b,d   Davis, Robert L ^b,f   Liu, Liyan ^b,e   Herrinton, Lisa ^b,e   Brown, Jeffrey S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HMO Research Network Center for Education and Research in Therapeutics   (United States)

^c Pharmacy Analytic Services   (United States)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

^e DIVISION OF RESEARCH   (United States)

^f Center for Health Research   (United States)

Author keywords

Analytic methods; Drug surveillance; Pharmacoepidemiology; Prospective analysis

Indexed keywords

VALPROATE SEMISODIUM;

ARTICLE; DATA EXTRACTION; DRUG SURVEILLANCE PROGRAM; EMERGENCY WARD; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; PILOT STUDY; PRIORITY JOURNAL; PROBABILITY; PRODUCT SAFETY; PROSPECTIVE STUDY; QUALITY CONTROL; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTICONVULSANTS; CHILD; DRUGS, GENERIC; EMERGENCY SERVICE, HOSPITAL; FEASIBILITY STUDIES; FEMALE; FRACTURES, BONE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK; TIME FACTORS; VALPROIC ACID; YOUNG ADULT;

EID: 84877612503     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3412     Document Type: Article

References (27)

1. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352(11):1092-1102.
2. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170(14):1191-1201.
3. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010;363(16):1489-1491.
4. Weiss-Smith S, Deshpande G, Chung S, Gogolak V. The FDA drug safety surveillance program: adverse event reporting trends. Arch Intern Med 2011;171(6):591-593.
5. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 2001;10(5):407-410.
6. Gibbons RD, Amatya AK, Brown CH, et al. Post-approval drug safety surveillance. Annu Rev Public Health 2010;31:419-437.
7. Alina Baciu KS, Sheila P. Burke, ed. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, D.C.: Institute of Medicine of the National Academies; 2006.
8. Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new sentinel network - improving the evidence of medical-product safety. N Engl J Med 2009;361:645-647.
9. Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System - a national resource for evidence development. N Engl J Med 2011;364(6):498-499.
10. Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010;171(2):177-188.
11. Hartzema AG, Racoosin JA, MaCurdy TE, Gibbs JM, Kelman JA. Utilizing Medicare claims data for real-time drug safety evaluations: is it feasible? Pharmacoepidemiol Drug Saf 2011;20(7):684-688.
12. Brown J, Moore K, Braun M, et al. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. Med Care 2009;47(12):1251-1257.
13. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):23-31.
14. Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012;21 Suppl 1:1-8.
15. Greene SK, Kulldorff M, Yin R, et al. Near real-time vaccine safety surveillance with partially accrued data. Pharmacoepidemiol Drug Saf 2011;20(6):583-590.
16. Brown JS, Kulldorff M, Petronis KR, et al. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations. Pharmacoepidemiol Drug Saf 2009;18(3):226-234.
17. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf 2007;16(12):1275-1284.
18. Maro JC, Brown JS. Impact of exposure accrual on sequential postmarket evaluations: a simulation study. Pharmacoepidemiol Drug Saf 2011;20(11):1184-1191.
19. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008;71(7):525-530.
20. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007;48(3):464-469.
21. Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003;25(6):1578-1592.
22. Devine ST, Weisbart E, Barron J, Behm A. Acute epilepsy exacerbations in patients switched between A-rated anti-epileptic drugs. Curr Med Res Opin 2010;26(2):455-463.
23. Lieu TA, Hinrichsen VL, Moreira A, Platt R. Collaborations in population-based health research: the 17th annual HMO Research Network Conference, March 23-25, 2011, Boston, Massachusetts, USA. Clin Med Res 2011;9(3-4):137-140.
24. Go AS, Magid DJ, Wells B, et al. The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research. Circ Cardiovasc Qual Outcomes 2008;1(2):138-147.
25. Wagner EH, Greene SM, Hart G, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr 2005(35):3-11.
26. Kulldorff M, Davis RL, Kolczak M, Lewis E, Lieu TA, Platt R. A maximized sequential probability ratio test for drug and vaccine safety surveillance. Seq Anal. 2011; 3(10): 58-78
27. Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007;45(10):S89-S95.